Clay B. Siegall, Ph.D.

President, Chief Executive Officer and Chairman of the Board

In 1998, Clay co-founded Seattle Genetics. It was a time when cancer treatments were dominated by chemotherapies that didn’t differentiate between killing cancer cells and normal cells. His vision was to improve the lives of people with cancer by developing targeted therapies to treat major unmet needs.

A scientist by training, Clay built Seattle Genetics on a foundation of scientific innovation, rigorous research and drug development practices as well as a passion for helping patients. He has guided the company to its current leadership position in the field of antibody-drug conjugates (ADCs) and in the 2011 FDA approval of our first ADC product, ADCETRIS® (brentuximab vedotin). Under a collaboration with Takeda Pharmaceutical Company, ADCETRIS is now a global brand that is approved in more than 65 countries. Seattle Genetics is also advancing a diverse pipeline of proprietary ADCs for the treatment of cancer.

Under Clay’s leadership, Seattle Genetics has entered in to multiple strategic licenses for our ADC technology, including with Astellas, Genentech (Roche), AbbVie, GlaxoSmithKline and Pfizer, that have generated more than $350 million to date. Across internal and collaborator programs, there are more than 20 ADCs in clinical development using our technology. Clay has also led Seattle Genetics’ capital-raising activities, securing more than $1.2 billion through public and private financings, including the company’s initial public offering in 2001.

Year joined:

1998 as co-founder

Experience:

Bristol-Myers Squibb Pharmaceutical Research Institute

National Institutes of Health, National Cancer Institute

Awards:

2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences

2012 Pacific Northwest Ernst & Young Entrepreneur of the Year

Publications/Patents:

Author on more than 70 publications

Holds 15 patents

Education:

Ph.D., Genetics, George Washington University

B.S., Zoology, University of Maryland

Boards:

Director, Ultragenyx Pharmaceutical

Director, Alder BioPharmaceuticals

Director, Washington Roundtable

Jonathan Drachman, M.D.

Chief Medical Officer and Executive VP, Research and Development

Jonathan was named Chief Medical Officer and Executive Vice President, Research and Development in October 2013 to lead the company’s research and development teams. Under his leadership, these teams are united to seamlessly move our scientific research into clinical development. His desire to provide the best possible treatment options for people with cancer drives our innovation.

Year joined:

2004

Other positions held:

Senior Vice President, Research and Translational Medicine

Vice President, Translational Medicine

Vice President, Early Clinical Development

Senior Medical Director

Medical Director

Experience:

Associate Professor in the Hematology Division, Department of Medicine at the University of Washington in Seattle

Senior Investigator in the Division of Research and Education and Medical Director of the Umbilical Cord Blood Program at the Puget Sound Blood Center

Education:

Residency in Internal Medicine and fellowship in Medical Oncology, University of Washington

M.D., Harvard Medical School

B.A. Biochemistry, Harvard University

Board:

Director, Calithera Biosciences

Todd E. Simpson

Chief Financial Officer

Todd brought his extensive industry experience in senior financial positions with public biotechnology companies to his role as our CFO. He’s leveraged that experience to grow our Finance, Information Technology and Facilities groups to accommodate the company’s continuing growth. Our campus, information and finance systems are well-positioned for fulfilling our mission.

Year joined:

2005

Experience:

Vice President, Finance and Administration and Chief Financial Officer, Targeted Genetics, 2001-2005

Vice President, Finance and Administration and Chief Financial Officer, Aastrom Biosciences, 1996-2001

Integra Life Sciences Corporation

Telios Pharmaceuticals, Inc. (acquired by Integra in 1995)

Ernst & Young LLP, 1983-1992 with a focus in life sciences and technology practices

Education:

Certified Public Accountant

B.S., Accounting and Computer Science, Oregon State University

Boards:

Director, Aquinox Pharmaceuticals

Director, Life Science Washington (formerly WBBA)

Vaughn B. Himes, Ph.D.

Chief Technical Officer

Vaughn has 25+ years of product development and commercialization experience in large pharmaceutical and biotechnology companies, with expertise in quality, manufacturing, technical operations, process development and scale-up activities. He leads the Seattle Genetics manufacturing, supply chain, process sciences and quality functions supporting our successful commercialization of ADCETRIS and a robust pipeline of product candidates. 

Year joined:

2009

Other positions held:

Executive Vice President, Process Sciences and Technical Operations

Experience:

Senior Vice President, Technical Operations - ZymoGenetics
Commercial and clinical manufacturing, supply chain and logistics, quality control and process development; responsible for CMC portion of successful BLA for Recothrom and commercial supply

Vice President, Worldwide Manufacturing Operations – Corixa
Commercial products include Bexxar and MPL

Experience cont.:

Vice President, Manufacturing Operations - Targeted Genetics
Manufacturing operations for clinical supply of gene delivery products

Vice President, Product Development - Genovo

Associate Director, Biological Development - Wyeth-Lederle Vaccines

Education:

Ph.D, Chemical Engineering, University of Minnesota

B.A., Chemistry, Pomona College

Darren Cline

Executive VP, Commercial

Darren has 20+ years of sales, marketing and managed markets experience in senior commercial roles at leading biotech technology companies. That experience was a key factor in our successful launch of ADCETRIS. He now leads our Commercial organization which includes Sales, Marketing, Managed Markets and Market Planning.

Year joined:

2010

Other positions held:

Senior Vice President, Commercial

Vice President, Marketing, Managed Markets and Reimbursements

Experience:

Vice President, Market Access, InterMune
Responsible for developing and leading overall Market Access strategy and execution for a late stage product candidate

Experience cont.:

Executive Director of Sales, Alexion
Commercial leadership role in successful U.S. launch of Soliris®

Sales, Marketing and Managed Markets leadership positions, Amgen

Education:

M.B.A., Pepperdine University

B.S., Marketing, San Diego State University

Jean I. Liu, J.D.

General Counsel, Executive VP, Legal Affairs

Jean oversees all aspects of the company’s legal, compliance and intellectual property functions and serves as Corporate Secretary. Her experience allows her to partner with management on the highest level of corporate strategic matters.

Year joined:

2014

Experience:

Vice President and General Counsel, Halozyme

Chief Legal Officer and Corporate Secretary and other roles, Durect Corporation

Pillsbury, Madison & Sutro (now Pillsbury Winthrop), Venture Law Group
Legal advising for early stage companies, including technology transfer, licensing, patents and copyright and trademark litigation

Education:

J.D, Columbia University

Harlan Fiske Stone Scholar

M.S., Biology, Stanford University

B.S., Cellular and Molecular Biology with highest distinction, University of Michigan

Christopher Pawlowicz

Executive VP, Human Resources

Chris has more than 30 years of human resources experience, principally in the pharmaceutical industry.

Year joined:

2008

Other positions held:

Senior Vice President, Human Resources

Experience:

Senior Vice President, Human Resources and Administration, MedPointe Pharmaceuticals
Part of the turnaround team that successfully restructured and sold the business to Meda Pharmaceuticals

Experience cont.:

Corporate Vice President, Human Resources, Express Scripts
The nation’s third largest pharmacy benefit management company

Senior human resources positions at Pharmacia, Searle and Monsanto
Global launch of Celebrex, the start-up of biotechnology teams in plant sciences, support of high growth commercial investments in Latin America, Europe and Asia, and post-merger integration of numerous companies

Education:

M.A., Labor and Industrial Relations, University of Illinois at Urbana-Champaign

B.A., Economics, Benedictine College, summa cum laude

Elaine Waller, Pharm.D.

Executive VP, Regulatory Affairs

Elaine had more than 20 years of experience in regulatory affairs and clinical research before joining Seattle Genetics. She has led multiple successful submissions to the Food and Drug Administration, including both our BLA and sBLA for brentuximab vedotin, leading to the approval of three indications for ADCETRIS.

Year joined:

2008

Other positions held:

Senior Vice President, Regulatory Affairs

Experience:

Senior Vice President, Regulatory Affairs/Quality Assurance and Clinical Research, Sonus Pharmaceuticals (until its merger with OncoGenex Pharmaceuticals)

Chief Operating Officer, Radiant Research

Experience cont.:

Senior positions in regulatory affairs and clinical research, Hoechst Marion Roussel and Marion Merrell Dow, predecessor companies to Sanofi

Teaching positions in graduate and undergraduate pharmacy education and Director of Clinical Research, Drug Dynamics Institute, University of Texas at Austin

Education:

Pharm.D., University of Missouri – Kansas City

M.B.A., Rockhurst College

B.S., Pharmacy, University of Missouri – Kansas City